The number of systemic anti-inflammatory therapies for dermatologic diseases in children is expected to grow in 2026.

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview: Sanofi and Regeneron have ...

Dupilumab, a fully human monoclonal antibody, inhibits the signaling of the interleukin 4 (IL-4) and IL-13 pathways.

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

In both studies, at 24 weeks, patients treated with dupilumab plus corticosteroid nasal spray experienced a 51% and 57% improvement in nasal congestion/obstruction severity vs 15% and 19% improvement ...

The top 5 most-read dermatology content of 2025 on AJMC.com included innovative advances from artificial intelligence ...

Please provide your email address to receive an email when new articles are posted on . Serum dupilumab levels showed no correlation to treatment response or adverse events in patients with atopic ...